Safety and efficacy of once-daily treatment with beclomethasone dipropionate nasal aerosol in subjects with perennial allergic rhinitis

Allergy and Asthma Proceedings

Volumn 33, Issue 3, 2012, Pages 249-257

  Meltzer, Eli O ^a   Jacobs, Robert L ^b   LaForce, Craig F ^c   Kelley, C Leith ^d   Dunbar, Stephanie A ^d   Tantry, Sudeesh K ^d  

^a ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^b Biogenics Research Institute   (United States)

^c North Carolina Clinical Research   (United States)

^d Teva Branded Pharmaceutical Products R and D Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; PLACEBO;

ADOLESCENT; ADULT; AEROSOL; AGED; ALLERGIC RHINITIS; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NASAL DISCOMFORT; NASAL PRURITUS; NOSE CONGESTION; OROPHARYNX PAIN; PAIN; PERENNIAL RHINITIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS QUALITY OF LIFE QUESTIONNAIRE; RHINORRHEA; SCHOOL CHILD; SCORING SYSTEM; SINUS HEADACHE; SNEEZING; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BECLOMETHASONE; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL SPRAYS; QUALITY OF LIFE; QUESTIONNAIRES; RHINITIS, ALLERGIC, PERENNIAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862119417     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3571     Document Type: Article

References (17)

1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(suppl 86):8-160, 2008.
2. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 122(suppl):S1-S84, 2008.
3. Skoner DP. Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108(suppl):S2-S8, 2001.
4. Greiner AN, Hellings PW, Rotiroti G, et al. Allergic rhinitis. Lancet 378:2112-2122, 2011.
5. Blaiss MS. Allergic rhinitis: Direct and indirect costs. Allergy Asthma Proc 31:375-380, 2010.
6. Bousquet J, and the ARIA Workshop Group. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108:S147-S334, 2001.
7. Weiner JM, Abramson MJ, and Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: Systematic review of randomised controlled trials. BMJ 317:1624-1629, 1998.
8. Luskin AT. Is there a role for aerosol nasal sprays in the treatment of allergic rhinitis. Allergy Asthma Proc 32:168-177, 2011.
9. Fromer LM, Ortiz G, Ryan SF, et al. Insights on allergic rhinitis from the patient perspective. J Fam Pract 61(suppl):S16-S22, 2012.
10. Naclerio RM, Hadley JA, Stoloff S, et al. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc 28:S11-S17, 2007.
11. Montreal Protocol. Available online at www.epa.gov/ozone/intpol/; accessed January 26, 2012.
12. QVAR 40 μg (beclomethasone dipropionate HFA, 40 μg) inhalation aerosol for oral inhalation only; QVAR 80 μg (beclomethasone dipropionate HFA, 80 μg) inhalation aerosol for oral inhalation only package insert. Teva Respiratory, LLC, Horsham, PA; www.qvar.com/PrescribingInformation.pdf; 2010.
13. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 98:843-845, 1996.
14. Kim K, Weiswasser M, and Nave R. Safety of once-daily ciclesonide nasal spray in children 2 to 5 years of age with perennial allergic rhinitis. Pediatr Asthma Allergy Immunol 20:229-249, 2007.
15. Blaiss MS. Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 32:413-418, 2011.
16. Barnes ML, Vaidyanathan S, Williamson PA, et al. The minimal clinically important difference in allergic rhinitis. Clin Exp Allergy 40:242-250, 2010.
17. van Bavel J, Amar NJ, Melchior A, et al. BDP HFA nasal aerosol 320 μg once daily is safe and effective in the treatment of nasal symptoms associated with seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 105:A121, 2010.